Equities
Health CarePharmaceuticals & Biotechnology
  • Price (HUF)8,795.00
  • Today's Change25.00 / 0.29%
  • Shares traded62.66k
  • 1 Year change+29.62%
  • Beta0.5587
Data delayed at least 15 minutes, as of Oct 22 2021 16:13 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Financials data is unavailable for this security.

Inc stmt in HUFIncome statement in HUFView more

Year on year Richter Gedeon Vegyeszeti Gyar Nyrt grew revenues 11.62% from 507.79bn to 566.78bn while net income improved 122.09% from 47.14bn to 104.68bn.
Gross margin55.18%
Net profit margin17.16%
Operating margin20.58%
Return on assets10.31%
Return on equity12.47%
Return on investment11.76%
More ▼

Cash flow in HUFView more

In 2020, Richter Gedeon Vegyeszeti Gyar Nyrt increased its cash reserves by 10.65%, or 13.69bn. The company earned 133.52bn from its operations for a Cash Flow Margin of 23.56%. In addition the company used 98.89bn on investing activities and also paid 18.29bn in financing cash flows.
Cash flow per share767.55
Price/Cash flow per share11.49
Book value per share4,403.71
Tangible book value per share3,043.41
More ▼

Balance sheet in HUFView more

Richter Gedeon Vegyeszeti Gyar Nyrt has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 142.07bn.
Current ratio3.15
Quick ratio2.09
Total debt/total equity0.0302
Total debt/total capital0.029
More ▼

Growth rates in HUF

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 257.30% and 122.14%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
Div yield(5 year avg)1.71%
Div growth rate (5 year)25.52%
Payout ratio (TTM)42.36%
EPS growth(5 years)14.13
EPS (TTM) vs
TTM 1 year ago
45.41
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.